

**Cited In for PMID: 26089548**

<< < Page 1 of 23 > >>

224 results

- 1 **68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.**

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ.
 J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.
 PMID: 26089548 [Free article](#).
- 2 **Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.**

Chen J, Qi L, Tang Y, Tang G, Gan Y, Cai Y.
 Front Cell Dev Biol. 2022 Aug 12;10:958180. doi: 10.3389/fcell.2022.958180. eCollection 2022.
 PMID: 36036001 [Free PMC article](#). Review.
- 3 **[68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer].**

Xie Y, Li C, Zhang L, Zang S, Yu F, Wang S, Wang F.
 Nan Fang Yi Ke Da Xue Xue Bao. 2022 Aug 20;42(8):1143-1148. doi: 10.12122/j.issn.1673-4254.2022.08.05.
 PMID: 36073212 [Free PMC article](#). Chinese.
- 4 **In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA.**

Prasad V, Huang K, Prasad S, Makowski MR, Czech N, Brenner W.
 Front Oncol. 2021 Mar 17;11:578093. doi: 10.3389/fonc.2021.578093. eCollection 2021.
 PMID: 33816225 [Free PMC article](#).
- 5 **Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications.**

Aluicio-Sarduy E, Thiele NA, Martin KE, Vaughn BA, Devaraj J, Olson AP, Barnhart TE, Wilson JJ, Boros E, Engle JW.
 Chemistry. 2020 Jan 27;26(6):1238-1242. doi: 10.1002/chem.201905202. Epub 2020 Jan 9.
 PMID: 31743504 [Free PMC article](#).
- 6 **Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.**

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M.
 EJNMMI Res. 2018 Oct 29;8(1):96. doi: 10.1186/s13550-018-0451-z.
 PMID: 30374743 [Free PMC article](#).
- 7 **Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.**

Abusalem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G.
 Cancers (Basel). 2023 Sep 13;15(18):4537. doi: 10.3390/cancers15184537.
 PMID: 37760506 [Free PMC article](#). Review.
- 8 **Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer.**

Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, Rose F, D'Alessandria C, Weber W, Wester HJ.
 J Nucl Med. 2022 Oct;63(10):1489-1495. doi: 10.2967/jnumed.121.263371. Epub 2022 Jan 27.
 PMID: 35086894 [Free PMC article](#).
- 9 **Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.**

Vorobyeva A, Westerlund K, Mitran B, Altai M, Rinne S, Sörensen J, Orlova A, Tolmachev V, Karlström AE.
 Sci Rep. 2018 Jun 25;8(1):9643. doi: 10.1038/s41598-018-27886-0.
 PMID: 29942011 [Free PMC article](#).

Patent Owner Exhibit 2132
IPR2025-01582

10 [Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.](#)

Czerwińska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A.

Molecules. 2020 Apr 10;25(7):1743. doi: 10.3390/molecules25071743.

PMID: 32290196 [Free PMC article](#). Review.[« First](#)[« Prev](#)Page 1 of 23 [Next >](#)[Last >>](#)

FOLLOW NCBI



Connect with NLM



National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

[Web Policies](#)
[FOIA](#)
[HHS Vulnerability Disclosure](#)
[Help](#)
[Accessibility](#)
[Careers](#)

[NLM](#) [NIH](#) [HHS](#) [USA.gov](#)